KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial.

N Harbeck, V Dieras, K A Gelmon, R S Finn, M Martin, P Neven, S Kim, J Ma, E Gauthier, E Broughton, J Doan, H S Rugo

ESMO Open 10(4) 104497

PMID40107156
PMCIDPMC11964640
DOI10.1016/j.esmoop.2025.104497
发表日期2025-03-19
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:已完成可用 Figure 的视觉复核,未识别到合格 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Metastatic breast cancer (mBC) remains incurable, highlighting the importance of patient-reported outcomes (PROs) in treatment decision making. In the randomized phase III PALOMA-2 trial, health-related quality of life (HRQoL) was maintained in patients receiving first-line palbociclib plus letrozole compared with placebo plus letrozole after a median follow-up of 22.3 months. However, little is known about HRQoL for patients taking palbociclib for an extended period of time. Here, we report the PRO results from the PALOMA-2 trial after a median follow-up time of 90 months. PATIENTS AND METHODS: Women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) mBC were randomly assigned 2 : 1 to receive palbociclib plus letrozole (n = 444) or placebo plus letrozole (n = 222). HRQoL was assessed with the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQoL five-dimensions three-level (EQ-5D-3L) questionnaires, administered on site on day 1 of cycles 1, 2, and 3 and then every other cycle from cycle 5 until study end. Treatment arm comparisons were made for change from baseline in QoL and time to deterioration in FACT-B (definitive definition, TTDD). RESULTS: After a median follow-up of 90 months, no significant differences between treatments were observed for overall change from baseline in FACT-B total, FACT-B subscales, and EQ-5D-3L scores. While TTDD did not differ between treatment arms, TTDD was shorter for patients with disease progression versus those without disease progression (hazard ratio 0.644, P < 0.001). Individual items assessing side-effects and hair loss favored the palbociclib plus letrozole arm versus the letrozole arm; no treatment difference was observed for items assessing pain. CONCLUSIONS: This extended follow-up analysis of PROs in PALOMA-2 shows continued QoL maintenance for patients with ER+/HER2- mBC receiving long-term palbociclib plus letrozole treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1FACT-B total and subscale scores: between-treatment comparison of overall change from baseline. Gray boxes indicate minimal clinically important differences for the breast cancer subscale (2 points), TOI index (5 points), FACT-G (5 points) and FACT-B (7 points). CI, confidence interval; FACT-B, Functional Assessment of Cancer Therapy-Breast; FACT-G, Functional Assessment of Cancer Therapy-General; TOI, trial outcome index.
非 KM Figure
Figure 2FACT-B total scores: between-treatment comparison of overall change from baseline by disease characteristics . FACT-B minimal clinically important difference is 7 points (shaded area). CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; Let, letrozole; Pal, palbociclib; Pbo, placebo; TFI, treatment-free interval.
非 KM Figure
Figure 3Kaplan–Meier plot of FACT-B time to deterioration (definitive definition). Variable used for stratification was site of disease (visceral versus nonvisceral). CI, confidence interval; FACT-B, Functional Assessment of Cancer Therapy-Breast; HR, hazard ratio; TTDD, time to definitive deterioration.
非 KM Figure